Jazz Pharmaceuticals : Zanidatamab R&D Day

March 19, 2024

Zanidatamab R&D Day

Differentiated and De-Risked

1	March 2024

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, and planned or anticipated regulatory submissions and filings; the Company's expectations with respect to its products and product candidates and the potential of the Company's products and product candidates, including expectations with respect to zanidatamab's de-risked, near term opportunity, the potential of zanidatamab to be more than a two billion dollar market opportunity with the potential to raise the standard of care for patients and create long-term value for the Company, and the potential regulatory path related thereto; and other statements that are not historical

facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the successful completion of development and regulatory activities with respect to the Company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients such as those experienced, and expected to be experienced, by the Company; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon its obtaining, maintaining and defending intellectual property protection for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in the Company's Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its future filings and reports. Other risks and uncertainties of which the Company is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

2	March 2024

Agenda

1. Mechanism of Action
2. Zanidatamab in BTC
3. Zanidatamab in GEA: Dr. Geoffrey Ku
4. Zanidatamab in Breast Cancer
5. • Late-Stage:Dr. Sara Hurvitz
   • HER2+/HR+: Dr. Santiago Escrivá-de-Romaní
   • Early-StageBreast Cancer: Dr. Paula Pohlmann
6. Roadmap to Success

3	March 2024

Zanidatamab

Bispecific HER2-Targeted mAb

4	March 2024

Zanidatamab Has the Potential to Transform HER2-Targeted Therapies

Zanidatamab is a highly active, differentiated HER2-targeted bispecific mAb

with early compelling survival data

Novel and		Best-in-Class		Compelling		$2B+
		Clinical Data		Commercial
Differentiated		Profile
		Supports Fast		Opportunity
MOA		Addresses
		to Market
		Unmet Need
			Strategy

HER2 = human epidermal growth factor receptor 2; mAb = monoclonal antibody; MOA = mechanism of action.

5

March 2024

Zanidatamab

Differentiated Leader in the HER2 space

6	March 2024

Rob Iannone, M.D., M.S.C.E.

Executive Vice President,

Global Head of Research & Development

Zanidatamab's Biparatopic Binding Drives Unique MOA and Clinical Activity

• Zanidatamab simultaneously binds two non-overlappingextracellular domains of HER2 (biparatopic binding)
• Unique geometry and binding properties result in multiple mechanisms of action

ADCC / ADCP = antibody-dependent cellular cytotoxicity / phagocytosis; C1q: complement component 1q protein complex; EGFR = epidermal growth factor receptor; Fc receptor = fragment crystallizable	8	March 2024
receptor; HER2 / 3 = human epidermal growth facto receptor 2 / 3; MOA = mechanism of action; NK cell = natural killer cell. Source: Weisser et al. Nat Commun. 2023;14(1):1394.

Zanidatamab's Biparatopic Binding Drives Unique MOA and Clinical Activity

• Binding properties of zanidatamab are believed to form the foundation of the unique and diverse mechanisms of action observed preclinically and clinically to-date
• Biparatopic binding and engagement of HER2 in trans results in formation of distinct and large HER2 caps / clusters on cell surface
• Trastuzumab (tras), pertuzumab (pert), or the combination of tras + pert were not observed to mediate the formation of HER2 caps, clusters or CDC

Zanidatamab Clusters HER2 Receptors on Cell Surface1

CDC = complement-dependent cytotoxicity; HER2 = human epidermal growth factor receptor 2; MOA = mechanism of action.1Weisser et al. Nat Commun. 2023;14(1):1394.

9

March 2024

Zanidatamab's Biparatopic Binding Drives Unique MOA and Clinical Activity

• Cap formation is believed to induce better effector activity1
• Zanidatamab exhibits strong activation of complement-dependent cytotoxicity (CDC)1

CDC1

Zanidatamab		Trastuzumab		Pertuzumab		Trastuzumab and Pertuzumab		Negative Control

ADCC = antibody-dependent cellular cytotoxicity; C1q = complement component 1q protein complex; C3a = 77 residue anaphylatoxin; C5a = protein fragment released from cleavage of complement component C5; MOA =	10	March 2024
mechanism of action; Reference image created with BioRender.com. 1Weisser et al. Nat Commun. 2023;14(1):1394.